Table 1.
COVID-19 in patients with hematologic malignancy: summary of studies of COVID-19 in >50 patients with hematologic malignancy
| Reference | Investigator | Patient population | Study design | Clinical severity (%) | Mortality (%) | Risk factors for severe COVID-19 |
|---|---|---|---|---|---|---|
| 9 | NCATS' National COVID Cohort Collaborative | 63 413 cancer patients with COVID-19 • 10.5% patients with HM |
Retrospective cohort | • Age ≥ 65 • Male sex • Southern or western US residence • Recent cytotoxic therapy |
||
| 8 | European Haematology Association Survey (EPICOVIDEHA) | 3 801 patients with HM with COVID-19 | Survey | Hospitalization (73.1) ICU (18.1) |
HM patients died (31.2) | • Age • Active malignancy • Chronic cardiac disease • Liver disease • Renal impairment • Smoking history • ICU stay |
| 10 | COVID-19 and Cancer Consortium Registry (CCC19) | 4 966 cancer patients with COVID-19 (10.5% patients with HM) | Registry | Hospitalization (57.8) | Cancer patients died (14) | • Older age • Male sex • Obesity • Cardiovascular and pulmonary comorbidities • Renal disease • Diabetes mellitus • Non-Hispanic Black race • Hispanic ethnicity • ECOG PS • Recent cytotoxic chemotherapy • Hematologic malignancy |
| 11 | Republic of Turkey, Ministry of Health database | 740 patients with HM with COVID-19 | Retrospective cohort | Hospital admission (61.1), ICU admission (18.9), Mechanical ventilation (13.8) | HM patients died (13.7) | |
| 15 | Italian Hematology Alliance on COVID-19 | 536 patients with HM with COVID-19 | Retrospective cohort | HM patients died (36.9%) | • Older age • Progressive disease status • AML • Indolent NHL • Aggressive NHL • Plasma cell neoplasms • Severe/critical COVID-19 |
|
| 12 | Argentine Society of Hematology | 419 patients with HM with COVID-19 | Survey | Hospital admission (64.9), ICU (24.1) | HM patients died (20.7) | • Comorbidities • Disease status • Previous chemotherapy |
| 13 | Republic of Turkey, Ministry of Health database | 497 patients with HM with COVID-19 • 6.9% SCT recipients |
Retrospective cohort | Mechanical ventilation (16.7) • MV in HCT recipients (15.6) |
HM patients died (12.1) • HCT recipients died (15.5) |
|
| 14 | European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) | 382 SCT recipients with COVID-19 | Prospective survey | SCT recipients died (28) | • Older age • Need for ICU • Moderate/high immunodeficiency |
|
| 16 | Spanish transplant group and cell therapy (GETH) | 367 patients with HM with COVID-19 • 33.5% SCT recipients |
Retrospective cohort | • Hospitalization (56.4) • Oxygen support (40.8) • ICU (9.8) |
HM patients died 28.6% (105) | • Age > 70 y • Uncontrolled hematologic disease • Neutropenia • CRP > 20 mg/dL |
| 17 | Turkish Society of Hematology, Infectious Complications and Supportive Care Working Party | 340 patients with HM with COVID-19 | Retrospective cohort | Hospitalization (73.8) | HM patients died (26.5) | • Disease status • Decreased life expectancy related to primary HM • ICU admission • Type of COVID-19 treatment |
| 18 | NHS England | 10 926 COVID-related deaths • 3.1% patients with HM |
Analytic platform OpenSAFELY | HM patients died (3.1) | • Male • Greater age and deprivation • Diabetes • Severe asthma • Ethnicity |
|
| 19 | SEMI-COVID-19 Registry in Spain | 2 111 immunosuppressed patients with COVID-19 • 15.7% patients with HM |
Retrospective cohort | HM patients died (41.9) | ||
| 20 | National Israeli Study | 313 patients with HM with COVID-19 | Retrospective cohort | Hospitalization (56.9) | HM patients died (19.1) | • Severe COVID-19 • Age ≥ 70 |
| 21 | Center for International Blood and Marrow Transplant Research (CIBMTR) | 318 SCT recipients with COVID-19 • 57.9% allogeneic • 42.1% autologous |
Retrospective cohort | Mechanical ventilation (14.2) | SCT recipients died (20.8) | Allogeneic cohort: • Age ≥ 50 • Male sex • COVID-19 < 12 mo after SCT Autologous cohort: • Lymphoma |
| 22 | Tertiary level medical institute in North India | 242 patients with HM with COVID-19 | Retrospective cohort of electronic database system | Mechanical ventilation (21.1) | HM patients died (19.8) | • Severity of COVID-19 • Secondary infection • Invasive MV |
| 23 | UK Coronavirus Cancer Monitoring Project (UKCCMP) | 1 044 cancer patients with COVID-19 • 21.5% patients with HM |
Prospective cohort | Cancer patients died (30.6) | • Age • Sex • HM with recent chemotherapy |
|
| 24 | Electronic health record data collected by the IBM Watson Health Explorys from 360 US hospitals | 306 640 patients with HM • 0.07% with COVID-19 |
Retrospective case-control of electronic records | • Leukemia • NHL • Lung cancer |
||
| 25 | Cancer centers in France | 425 cancer patients with COVID-19 • 38.2% patients with HM |
Observational prospective | Cancer patients died (27.9) | • Male sex • Metastatic disease • History of inflammatory or autoimmune disease • Receiving immunosuppressive treatments • Lymphopenia ≤ 0.7 G/L |
|
| 26 | 11 centers across India | 130 HM with COVID-19 | Retrospective cohort | Oxygen support (51.5), Mechanical ventilation (29.2) |
HM patients died (20) | • Age ≥ 60 • Severe COVID • Disease status |
| 27 | Italian north-eastern Veneto Region | 1 090 cancer patients with COVID-19 • 124 HM with COVID-19 |
Retrospective population-based study | • Prevalent-active disease • Recent chemotherapy and radiotherapy |
||
| 28 | Guy's Cancer Centre and King's College Hospital in London | 306 cancer patients • 11.4% patients with HM |
Retrospective cohort | HM patients died (31.6) | • Male sex • Asian ethnicity • Hematologic malignancy • Cancer diagnosis > 2 y |
|
| 29 | 2 hematologic departments located in Lombardy, Italy | 102 HM with COVID-19 | HM patients died (39.2) | • Active hematologic treatment • Oxygen supplementation |
||
| 30 | single hematology center in the Czech Republic | 96 HM with COVID-19 | HM patients died (15.6) | • Age ≥ 60 | ||
| 31 | King’s College Hospital | 80 HM with COVID-19 | Retrospective cohort | HM patients died (35) | ||
| 11 | Republic of Turkey, Ministry of Health database | 77 HM with COVID-19 | Retrospective cohort | Mechanical ventilation (20.8) | HM patients died (20.8) | |
| 34 | Memorial Sloan-Kettering Cancer Center | 309 cancer patients with COVID-19 • 23.9% patients with HM |
Hospital admission (47.6) | Cancer patients died (10) | • Active hematologic or lung malignancy • Lymphopenia • Baseline neutropenia |
|
| 35 | London North West University Healthcare NHS Trust | 69 patients with HM with COVID-19 | Retrospective cohort | HM patients died (31.9) | ||
| 32 | Memorial Sloan-Kettering Cancer Center | 77 cellular therapy recipients with COVID-19 | Retrospective cohort | Cellular therapy recipients died (36.4) | ||
| 36 | Regional network of 7 hospitals | 66 HM with COVID-19 | Retrospective cohort | HM patients died (51.5) | ||
| 37 | Danish hematology departments | 66 HM with COVID-19 | ICU (21.2) | HM patients died (24.2) | • Older patients • Severe/critical COVID-19 • Comorbidity • High ECOG PS • Purine analog treatment • Acute leukemia/MDS |
|
| 38 | 4 hospitals in Europe: Spain, Northern-Italy and the Netherlands | 59 HM with COVID-19 | Retrospective cohort | HM patients died (33.9) | • | |
| 39 | Institute of Immunity and Transplantation, University College London | 55 HM with COVID-19 | Retrospective cohort | CPAP (34.5), endotracheal intubation (10.9) | HM patients died (34.5) | • CRP • Age • Ethnicity |
| 40 | New York Hospital System | 218 cancer patients with COVID-19 • 24.8% patients with HM |
Retrospective cohort | Cancer patients died (28) • HM patients died (37) |
• Older age • Multiple comorbidities • ICU support • D-dimer • Lactate dehydrogenase • Lactate |
|
| 41 | NHS Hospitals in England | 179 cancer patients with COVID-19 • 29.1% patients with HM |
Retrospective cohort | Cancer patients died (36.9) • HM patients died (48.1) |
• Age | |
| 42 | Gustave Roussy in France | 51 HM with COVID-19 | • Hypogammaglobulinemia • SARS-CoV-2 viremia |
AML, acute myeloid leukemia; CPAP, continuous positive airway pressure; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group Performance Status; MDS, myelodysplastic syndrome; MV, mechanical ventilation; NCATS, National Center for Advancing Translational Sciences; NHL, non-Hodgkin lymphoma; NHS, National Health Service; SCT, stem cell transplantion; SEMI, Sociedad Espanola de Medicina interna; US, United States.